1. Key Insights

2. Non-Cystic Fibrosis Bronchiectasis Overview at a Glance
2.1. Patient Share (%) Distribution of NCFB in 2017
2.2. Patients Share (%) Distribution of NCFB in 2030

3. Disease Background and Overview
3.1. Introduction
3.2. Etiology and manifestations
3.3. Symptoms
3.4. Pathophysiology
3.5. Diagnosis
3.6. Prognosis

4. Treatment and management

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Total Prevalence of Non-cystic Fibrosis Bronchiectasis in 7MM

6. Country Wise-Epidemiology
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Prevalence of Non-cystic fibrosis bronchiectasis
6.1.3. Diagnose prevalence of NCFB in United States
6.1.4. Gender Specific Diagnosed prevalence NCFB in United States
6.1.5. Severity Specific Diagnosed prevalence NCFB in United States
6.1.6. Etiology associated with NCFB in United States
6.1.7. Microbiology of NCFB patients in United States
6.2. EU-5
6.2.1. Assumptions and Rationale
6.2.2. Germany
6.2.2.1. Prevalence of Non-cystic fibrosis bronchiectasis
6.2.2.2. Diagnose prevalence of NCFB in Germany
6.2.2.3. Gender Specific Diagnosed prevalence NCFB in Germany
6.2.2.4. Severity Specific Diagnosed prevalence NCFB in Germany
6.2.2.5. Etiology associated with NCFB in Germany
6.2.2.6. Microbiology of NCFB patients in Germany
6.2.3. France
6.2.3.1. Prevalence of Non-cystic fibrosis bronchiectasis in France
6.2.3.2. Diagnose prevalence of NCFB in France
6.2.3.3. Gender Specific Diagnosed prevalence NCFB in France
6.2.3.4. Severity Specific Diagnosed prevalence NCFB in France
6.2.3.5. Etiology associated with NCFB in France
6.2.3.6. Microbiology of NCFB patients in France
6.2.4. Italy
6.2.4.1. Prevalence of Non-cystic fibrosis bronchiectasis in Italy
6.2.4.2. Diagnose prevalence of NCFB in Italy
6.2.4.3. Gender Specific Diagnosed prevalence NCFB in Italy
6.2.4.4. Severity Specific Diagnosed prevalence NCFB in Italy
6.2.4.5. Etiology associated with NCFB in Italy
6.2.4.6. Microbiology of NCFB patients in Italy
6.2.5. Spain
6.2.5.1. Prevalence of Non-cystic fibrosis bronchiectasis in Spain
6.2.5.2. Diagnose prevalence of NCFB in Spain
6.2.5.3. Gender Specific Diagnosed prevalence NCFB in Spain
6.2.5.4. Severity Specific Diagnosed prevalence NCFB in Spain
6.2.5.5. Etiology associated with NCFB in Spain
6.2.5.6. Microbiology of NCFB patients in Spain
6.2.6. United Kingdom
6.2.6.1. Prevalence of Non-cystic fibrosis bronchiectasis in the UK
6.2.6.2. Diagnose prevalence of NCFB in the UK
6.2.6.3. Gender Specific Diagnosed prevalence NCFB in UK
6.2.6.4. Severity Specific Diagnosed prevalence NCFB in UK
6.2.6.5. Etiology associated with NCFB in UK
6.2.6.6. Microbiology of NCFB patients in UK
6.3. Japan
6.3.1. Assumptions and Rationale
6.3.2. Prevalence of Non-cystic fibrosis bronchiectasis in Japan
6.3.3. Diagnose prevalence of NCFB in Japan
6.3.4. Gender Specific Diagnosed prevalence NCFB in Japan
6.3.5. Severity Specific Diagnosed prevalence NCFB in Japan
6.3.6. Etiology associated with NCFB in Japan
6.3.7. Microbiology of NCFB patients in Japan

7. Unmet needs

8. Appendix
8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables
Table 1: Conditions associated with the development of bronchiectasis
Table 2: Total Prevalent Population of NCFB in 7MM (2017-2030)
Table 3: Prevalent Population of NCFB in the United States (2017-2030)
Table 4: Diagnosed Prevalent Population of NCFB in the United States (2017-2030)
Table 5: Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
Table 6: Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
Table 7: Etiology associated with NCFB in the United States (2017-2030)
Table 8: Microbiology of NCFB patients in the United States (2017-2030)
Table 9: Prevalent Population of NCFB in the Germany (2017-2030)
Table 10: Diagnosed Prevalent Population of NCFB in Germany (2017-2030)
Table 11: Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
Table 12: Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
Table 13: Etiology associated with NCFB in the Germany (2017-2030)
Table 14: Microbiology of NCFB patients in Germany (2017-2030)
Table 15: Prevalent Population of NCFB in France (2017-2030)
Table 16: Diagnosed Prevalent Population of NCFB in France (2017-2030)
Table 17: Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
Table 18: Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
Table 19: Etiology associated with NCFB in France (2017-2030)
Table 20: Microbiology of NCFB patients in France (2017-2030)
Table 21: Prevalent Population of NCFB in Italy (2017-2030)
Table 22: Diagnosed Prevalent Population of NCFB in Italy (2017-2030)
Table 23: Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
Table 24: Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
Table 25: Etiology associated with NCFB in Italy (2017-2030)
Table 26: Microbiology of NCFB patients in Italy (2017-2030)
Table 27: Prevalent Population of NCFB in the Spain (2017-2030)
Table 28: Diagnosed Prevalent Population of NCFB in Spain (2017-2030)
Table 29: Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
Table 30: Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
Table 31: Etiology associated with NCFB in Spain (2017-2030)
Table 32: Microbiology of NCFB patients in Spain (2017-2030)
Table 33: Prevalent Population of NCFB in the UK (2017-2030)
Table 34: Diagnosed Prevalent Population of NCFB in the UK (2017-2030)
Table 35: Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
Table 36: Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
Table 37: Etiology associated with NCFB in the UK (2017-2030)
Table 38: Microbiology of NCFB patients in the UK (2017-2030)
Table 39: Prevalent Population of NCFB in Japan (2017-2030)
Table 40: Diagnosed Prevalent Population of NCFB in Japan (2017-2030)
Table 41: Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
Table 42: Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
Table 43: Etiology associated with NCFB in Japan (2017-2030)
Table 44: Microbiology of NCFB patients in Japan (2017-2030)

List of Figures
Figure 1: Common symptoms associated with non-CF bronchiectasis
Figure 2: Morphology of healthy and dilated bronchi
Figure 3: Representation of the cycle that leads to the development of bronchiectasis, as described by Cole
Figure 4: Airway obstruction, impaired mucociliary clearance, and other mechanisms promoting bronchiectasis
Figure 5: Algorithm for the diagnosis and etiologic investigation of bronchiectasis
Figure 6: Algorithm for the therapeutic management of stable bronchiectasis patients
Figure 7: Total Prevalent Population of NCFB in 7 MM (2017-2030)
Figure 8: Prevalent Population of NCFB in the United States (2017-2030)
Figure 9: Diagnosed Population of NCFB in the United States (2017-2030)
Figure 10: Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
Figure 11: Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
Figure 12: Etiology associated with NCFB in the United States (2017-2030)
Figure 13: Microbiology of NCFB patients in the United States (2017-2030)
Figure 14: Prevalent Population of NCFB in Germany (2017-2030)
Figure 15: Diagnosed Population of NCFB in Germany (2017-2030)
Figure 16: Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
Figure 17: Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
Figure 18: Etiology associated with NCFB in the Germany (2017-2030)
Figure 19: Microbiology of NCFB patients in Germany (2017-2030)
Figure 20: Prevalent Population of NCFB in France (2017-2030)
Figure 21: Diagnosed Population of NCFB in France (2017-2030)
Figure 22: Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
Figure 23: Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
Figure 24: Etiology associated with NCFB in France (2017-2030)
Figure 25: Microbiology of NCFB patients in France (2017-2030)
Figure 26: Prevalent Population of NCFB in Italy (2017-2030)
Figure 27: Diagnosed Population of NCFB in Italy (2017-2030)
Figure 28: Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
Figure 29: Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
Figure 30: Etiology associated with NCFB in Italy (2017-2030)
Figure 31: Microbiology of NCFB patients in Italy (2017-2030)
Figure 32: Prevalent Population of NCFB in Spain (2017-2030)
Figure 33: Diagnosed Population of NCFB in Spain (2017-2030)
Figure 34: Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
Figure 35: Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
Figure 36: Etiology associated with NCFB in Spain (2017-2030)
Figure 37: Microbiology of NCFB patients in Spain (2017-2030)
Figure 38: Prevalent Population of NCFB in the UK (2017-2030)
Figure 39: Diagnosed Population of NCFB in the UK (2017-2030)
Figure 40: Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
Figure 41: Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
Figure 42: Etiology associated with NCFB in the UK (2017-2030)
Figure 43: Microbiology of NCFB patients in the UK (2017-2030)
Figure 44: Prevalent Population of NCFB in Japan (2017-2030)
Figure 45: Diagnosed Population of NCFB in Japan (2017-2030)
Figure 46: Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
Figure 47: Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
Figure 48: Etiology associated with NCFB in Japan (2017-2030)
Figure 49: Microbiology of NCFB patients in Japan (2017-2030)
Figure 50: Unmet Needs